FIELD: biochemistry.
SUBSTANCE: invention relates to mutant protein of p-hydroxyphenylpyruvatedioxygenase (hereinafter – HPPD) or its biologically active fragment, which gives plants resistance or tolerance to HPPD-inhibiting herbicides. Isolated polynucleotide containing a nucleic acid sequence encoding mutant HPPD or its biologically active fragment, fused protein, a nucleic acid structure, an expression vector, and a host cell containing polynucleotide are also proposed. A method for obtainment of a plant having increased resistance or tolerance to HPPD-inhibiting herbicide compared to a plant with HPPD genes of a wild type, a plant obtained by the method, as well as a method for increasing resistance or tolerance of a plant cell, plant tissue, a plant part, or a plant to an herbicide inhibiting HPPD, compared to a plant cell, plant tissue, a plant part, or a plant with HPPD genes of a wild type, including expression of mutant HPPD, or its biologically active fragment, or the above-mentioned fused protein, are also proposed.
EFFECT: invention allows for obtainment of plants having resistance or tolerance to herbicides inhibiting HPPD, while the specified mutant HPPD saves or enhances a capability of catalyzation of conversion of para-hydroxyphenylpyruvate (HPP) into homogenizate, and it is significantly less sensitive to herbicides inhibiting HPPD, than HPPD of a wild type.
22 cl, 17 dwg, 14 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
MUTANT POLYPEPTIDE HYDROXYPHENYLPYRUVATE DIOXYGENASE, CODING GENE THEREOF AND USE THEREOF | 2019 |
|
RU2822892C1 |
CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
METHOD FOR OBTAINING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES | 2018 |
|
RU2795970C2 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
Authors
Dates
2022-10-18—Published
2019-05-31—Filed